학술논문

Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor of Disease-free Survival in Postnephrectomy High-risk Locoregional Renal Cell Carcinoma: Analysis of the S-TRAC Trial
Document Type
article
Source
Clinical Cancer Research. 26(18)
Subject
Biomedical and Clinical Sciences
Clinical Sciences
Oncology and Carcinogenesis
Cancer
Clinical Research
Clinical Trials and Supportive Activities
Kidney Disease
Rare Diseases
Evaluation of treatments and therapeutic interventions
6.1 Pharmaceuticals
Adult
Aged
Aged
80 and over
Carcinoma
Renal Cell
Chemotherapy
Adjuvant
Clinical Trials
Phase III as Topic
Disease-Free Survival
Feasibility Studies
Female
Humans
Kaplan-Meier Estimate
Kidney Neoplasms
Lymphocyte Count
Lymphocytes
Male
Middle Aged
Multicenter Studies as Topic
Neoplasm Recurrence
Local
Nephrectomy
Neutrophils
Prognosis
Randomized Controlled Trials as Topic
Risk Assessment
Sunitinib
Young Adult
Oncology & Carcinogenesis
Clinical sciences
Oncology and carcinogenesis
Language
Abstract
PurposeIn the S-TRAC trial, adjuvant sunitinib improved disease-free survival (DFS) compared with placebo in patients with locoregional renal cell carcinoma (RCC) at high risk of recurrence. This post hoc exploratory analysis investigated the neutrophil-to-lymphocyte ratio (NLR) for predictive and prognostic significance in the RCC adjuvant setting.Experimental designKaplan-Meier estimates and Cox proportional analyses were performed on baseline NLR and change from baseline at week 4 to assess their association with DFS. Univariate P values were two-sided and based on an unstratified log-rank test.Results609 of 615 patients had baseline NLR values; 574 patients had baseline and week 4 values. Sunitinib-treated patients with baseline NLR